President Donald Trump announced Monday that the U.S. Food and Drug Administration will begin notifying physicians of a “strong recommendation” for pregnant women to limit use of the common pain-reliever acetaminophen (Tylenol), suggesting its use may be linked to an increased risk of autism in children.
Trump stood beside Health and Human Services Secretary Robert F. Kennedy Jr. and said the federal government is “taking action now” amid rising autism rates. He emphasized pregnant women should avoid the over-the-counter drug unless medically necessary—such as in the case of a high fever—arguing that “there’s no downside” to greater caution.
The announcement diverges sharply from existing obstetric guidance, which considers acetaminophen one of the safest options for pain and fever in pregnancy when used as directed. Major maternal-health organisations and medical professionals have cautioned that the claim remains unproven and that untreated pain or fever in a pregnant woman can pose serious risks to both mother and baby.
The move triggered immediate reactions from pharmaceutical stakeholders: Tylenol’s manufacturer, Kenvue, reaffirmed that decades of published research show no confirmed causal link between acetaminophen and autism. Meanwhile, medical-profession groups flagged the sudden change in messaging as potentially confusing for women and their healthcare providers.
Independent experts note that while some observational studies have pointed to a possible association between prenatal acetaminophen exposure and neurodevelopmental disorders, no large-scale clinical trial has established causation, and many confounding factors—including maternal illness—make interpretation of the data difficult.
Critics also highlight that shifting an established recommendation based on preliminary findings could prompt pregnant women to delay treatment for fever or pain, both of which can carry risk in pregnancy. As the announcement reverberates across the medical community and among expectant-parents forums, questions loom about how the administration will support clear clinical guidance and reassure healthcare providers and patients alike.